- Home
- GLUE vs GTY Comparison
GLUE vs GTY Comparison
Compare GLUE & GTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLUE | GTY |
|---|---|---|
| Founded | 2019 | 1955 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2021 | 1998 |
Fundamental Metrics
Financial Performance| Metric | GLUE | GTY |
|---|---|---|
| Price | $23.69 | $34.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | $32.00 | ★ $32.60 |
| AVG Volume (30 Days) | ★ 1.5M | 557.6K |
| Earning Date | 05-08-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 5.92% |
| EPS Growth | N/A | ★ 8.00 |
| EPS | N/A | ★ 0.43 |
| Revenue | $123,672,000.00 | ★ $221,727,000.00 |
| Revenue This Year | N/A | $9.39 |
| Revenue Next Year | $2.45 | $7.83 |
| P/E Ratio | ★ $72.42 | $80.44 |
| Revenue Growth | ★ 63.54 | 9.02 |
| 52 Week Low | $4.12 | $25.39 |
| 52 Week High | $25.77 | $34.91 |
Technical Indicators
Market Signals| Indicator | GLUE | GTY |
|---|---|---|
| Relative Strength Index (RSI) | 66.36 | 63.04 |
| Support Level | $17.35 | $32.41 |
| Resistance Level | $25.56 | $34.75 |
| Average True Range (ATR) | 1.57 | 0.54 |
| MACD | 0.37 | 0.12 |
| Stochastic Oscillator | 78.95 | 89.45 |
Price Performance
Historical ComparisonAbout GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
About GTY Getty Realty Corporation
Getty Realty Corp is a net lease real estate investment trust in the U.S.A, specializing in the acquisition, financing, and development of convenience, automotive, and other single-tenant retail real estate. The company's portfolio includes convenience stores, express tunnel car washes, automotive service centers (gasoline and repair, oil and maintenance, tire and battery, and collision), drive-thru quick service restaurants, and certain other freestanding retail properties. It generates maximum revenue in the form of rental income.